Monday 01 June 2026
Internal Reference Number: FOI_9378
Date Request Received: 30/04/2026 00:00:00
Date Request Replied To: 21/05/2026 00:00:00
This response was sent via: By Email
Request Summary: BPA Q1 2026
Request Category: Companies
| Question Number 1: I would like to request the following information for Q1 2026 (January–March 2026). Please provide total volume (IU/mg) and, where available, total number of patients treated for the following products: • NovoSeven (eptacog alfa) • Cevenfacta (eptacog beta) • FEIBA (anti-inhibitor coagulant complex) • Obizur (susoctocog alfa) • Hemlibra (emicizumab) (haemophilia A inhibitor patients only) Where feasible from existing records, I would also welcome any available breakdown of these patient numbers and/or volumes by indication. For example: • haemophilia A with inhibitors • haemophilia B with inhibitors • Acquired haemophilia (AHA) • Glanzmann thrombasthenia • Factor VII deficiency • other (please specify) Partial breakdowns (e.g. for only some indications) are welcome. If this level of detail is not routinely captured, please provide the data in the closest available format, or without any indication breakdown. | |
| Answer To Question 1: Please see attachment. To accompany this answer to question 1 please also see the documents listed below:  FOI_9378 May 26.xlsx | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
